The study evaluated the efficacy, safety and tolerability of an innovative, proprietary, 28mg once-daily extended-release formulation of Namenda (memantine HCl) compared to placebo in outpatients with moderate to
CS-8958 is a long acting neuraminidase inhibitor (LANI), and is co-owned with Daiichi-Sankyo. The Phase II clinical trial was designed to test the safety and efficacy of CS-8958
This multi-center open-label clinical trial enrolled 106 Hispanic men and women from across the US. Patients were at least 50 years of age and had a diagnosis of
The results demonstrate that MEM 68626 is effective in models of cognition that are considered predictive of efficacy in Alzheimer’s disease and mild cognitive impairment. In addition, the
Under the expanded agreement, in addition to commercializing SensiGen’s advanced test for human papillomavirus exclusively on Sequenom’s MassArray platform, SensiGen will also be the exclusive provider of MassArray
Protect sites in the US will serve to provide the FDA with US-specific data on the post-market experience with the Endeavor stent. The US sites will enroll a
Their stake was purchased from Biggar, a charitable foundation that is said to be ThromboGenics’s largest shareholder. Biggar now holds a 9.8% stake in ThromboGenics following this transaction,
The Phase II prospective, randomized, dose-ranging study is evaluating the safety and efficacy of PF-4523655 versus laser therapy in 160 diabetic macular edema (DME) patients at multiple centers
Abiomed expects to begin facility preparations immediately and currently anticipates that the first Impella 2.5 cardiac assist device production line will be operational in approximately eighteen months. Abiomed’s
The data also indicated that GGF2 provided more benefit than other neuregulin fragments that were also tested. In preclinical testing, neuregulins have shown the potential to reduce and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.